Liminatus Pharma, Inc. Class A Common Stock (LIMN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Liminatus Pharma, Inc. Class A Common Stock (LIMN) has a cash flow conversion efficiency ratio of 0.365x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-600.61K) by net assets ($-1.65 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Liminatus Pharma, Inc. Class A Common Stock - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how Liminatus Pharma, Inc. Class A Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Liminatus Pharma, Inc. Class A Common St balance sheet liabilities for a breakdown of total debt and financial obligations.
Liminatus Pharma, Inc. Class A Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Liminatus Pharma, Inc. Class A Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
C&C Group plc
LSE:CCR
|
0.072x |
|
Golden State Mining Ltd
AU:GSM
|
-1.834x |
|
DXN Ltd
AU:DXN
|
-0.368x |
|
Brera Holdings PLC Class B Ordinary Shares
NASDAQ:BREA
|
-0.436x |
|
Wickes Group PLC
LSE:WIX
|
1.293x |
|
Zephyr Minerals Ltd
V:ZFR
|
0.006x |
|
Wirtek A/S
CO:WIRTEK
|
0.175x |
|
Volt Carbon Technologies Inc
V:VCT
|
-0.054x |
Annual Cash Flow Conversion Efficiency for Liminatus Pharma, Inc. Class A Common Stock (2021–2024)
The table below shows the annual cash flow conversion efficiency of Liminatus Pharma, Inc. Class A Common Stock from 2021 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Liminatus Pharma, Inc. Class A Common St.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-15.87 Million | $-3.11 Million | 0.196x | -37.43% |
| 2023-12-31 | $-10.69 Million | $-3.35 Million | 0.313x | +146.59% |
| 2022-12-31 | $1.29 Million | $-869.00K | -0.671x | -13974.82% |
| 2021-12-31 | $254.87 Million | $-1.22 Million | -0.005x | -- |
About Liminatus Pharma, Inc. Class A Common Stock
Liminatus Pharma, Inc. operates as a pre-clinical stage biopharmaceutical company that develops novel cancer therapies. It is developing CD47, a high affinity humanized anti CD47 antibody that has the potential to translate into clinic for CD47 SIRPa blocking and restoring the anti-tumor function of innate immune cells without inducing hemagglutination or hemolysis. The company was founded in 201… Read more